One-year results for STELARA in Crohn’s disease – The head-to-head SEAVUE Study

Returning guest, Dr. Andrew Greenspan, Vice President of Immunology Medical Affairs at Janssen discusses recent data from the Phase 3b SEAVUE study, the first head-to-head study of biologic therapies in patients with Crohn’s disease, evaluating the safety and efficacy of STELARA® (ustekinumab) compared with adalimumab through one year of treatment in biologic-naïve patients. These data were presented at this year’s Digestive Disease Week (DDW) Virtual 2021, where Janssen Immunology presented 20 abstracts in total from the company’s gastroenterology portfolio and pipeline.

Read More

How BD Is Getting The Country’s Elite Athletes Back on Track

Tony Ezell, President, North America and Chief Marketing Officer of BD (Becton, Dickinson and Company), discusses how BD and USA Track & Field (USATF) are working together to help get athletes back on the track safely through the use of rapid COVID-19 testing with the BD Veritor™ Plus System. In addition to helping athletes get safely back to competition as the official COVID-19 testing sponsor of USATF, the BD Veritor™ Plus System is helping the public get back on track with their normal lives. Ezell shares how BD has been at the forefront of the COVID-19 response, and how it will continue to support our continued return to normalcy.  

Read More

Amyloidosis – A Puzzle Finally Solved

Amyloidosis is a serious health condition that often goes undiagnosed – leading to improper management and heavy symptom burden on patients and families. New research presented at the 2021 American Geriatrics Society’s annual meeting shows the benefit of early diagnosis, the role of genetics, and the benefit of an amyloid specialist. Dr. Sharon Levine, MD, AGSF, Section Head, Geriatric Medicine, Division of Palliative Care and Geriatric Medicine in Boston, MA, and Andrea Kurkul, RP, Nurse Practitioner in Boston, MA, are here to discuss these findings and their study, “A Puzzle Finally Solved”.  

Read More

Enveric Biosciences – Clinical Development of Cannabinoids and Psychedelics

Enveric Biosciences recently announced that it has signed a definitive agreement to acquire MagicMed Industries, a pharmaceutical drug discovery and development platform focused on new-generation psychedelic molecular compounds and derivatives.With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules. Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD. Upon closing, Dr. Joseph Tucker will be appointed Enveric Biosciences CEO and David Johnson as Executive Chairman. 

Read More

Migraine – Brain – Gut Connection

Ed Fairburn, artist and one of the millions who has lived with migraine, discusses his unique art form using maps as portraits to show the complexities of migraine. He is joined by neurologist and headache specialist Dr. Lauren Natbody who discusses the impact of migraine and the emerging understanding of the brain/gut connection.  They talk about a new educational program called “Reroute Migraine Relief“, which aims to raise awareness of the complexities of migraines.

Read More

AstraZeneca EULAR Data Supports Next-Wave of Lupus Treatment

Dr. Joan Merrill, MD, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Research Program, US, discusses new Phase 3 data presented during the annual European Congress of Rheumatology (EULAR 2021) on anifrolumab that showed significant improvements in rash and arthritis in patients with systemic lupus erythematosus (SLE). Anifrolumab’s application in SLE is under review by regulatory authorities in the US, EU and Japan, with decisions anticipated in the second half of 2021.  

Read More

Gout Awareness

Dr. Robert Keenan, Adjunct Clinical Professor at Duke University School of Medicine discusses gout, how serious gout can be if left unmanaged which can lead to long-term issues like bone erosion and joint damage; and what it means to have uncontrolled gout, (meaning it can’t be controlled with treatment) which can lead to issues like chronic kidney disease, diabetes, and heart disease.  He talks about how stigma around the condition often prevents people from getting help because they think they are to blame for poor food choices but factors like genetics and preexisting conditions play a much larger role. 

Read More

Vision Health is Wealth

Vision care must be a core part of the concept that “health is wealth.”  Dr. Mark Ruchman, Chief Medical Officer at Versant Health, a managed vision care and benefits company, discusses the social and financial impact of eye disease; everyday steps people can take to protect their eye health; the most common eye diseases and their financial costs; and how telemedicine is being integrated into treatment plans. 

Read More

Non-radiographic Axial Spondyloarthritis Receives New, Specific ICD-10 Sub-Category

Returning guest, Dr. Jeffrey Stark, M.D., Head of U.S. Medical Immunology at UCB discusses the new, ICD-10 sub-category, M45.A for non-radiographic axial spondyloarthritis (nr-axSpA), a chronic inflammatory condition affecting the spine and sacroiliac joint, and the importance of this development for physicians, patients, and their families.  The new sub-category will be effective for diagnoses starting October 1, 2021. 

Read More